company background image
ISR

Isoray NYSEAM:ISR Stock Report

Last Price

US$0.29

Market Cap

US$40.8m

7D

-15.5%

1Y

-56.0%

Updated

26 Sep, 2022

Data

Company Financials +
ISR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ISR Stock Overview

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.

Isoray, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Isoray
Historical stock prices
Current Share PriceUS$0.29
52 Week HighUS$0.69
52 Week LowUS$0.25
Beta0.87
1 Month Change-28.02%
3 Month Change4.71%
1 Year Change-56.02%
3 Year Change-10.51%
5 Year Change-46.63%
Change since IPO-71.30%

Recent News & Updates

Shareholder Returns

ISRUS BiotechsUS Market
7D-15.5%-5.3%-6.9%
1Y-56.0%-30.6%-23.7%

Return vs Industry: ISR underperformed the US Biotechs industry which returned -30% over the past year.

Return vs Market: ISR underperformed the US Market which returned -23% over the past year.

Price Volatility

Is ISR's price volatile compared to industry and market?
ISR volatility
ISR Average Weekly Movement9.2%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: ISR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ISR's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
199861Lori Holmes-Woodshttps://isoray.com

Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.

Isoray, Inc. Fundamentals Summary

How do Isoray's earnings and revenue compare to its market cap?
ISR fundamental statistics
Market CapUS$40.77m
Earnings (TTM)-US$6.25m
Revenue (TTM)US$11.00m

3.7x

P/S Ratio

-6.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ISR income statement (TTM)
RevenueUS$11.00m
Cost of RevenueUS$5.96m
Gross ProfitUS$5.04m
Other ExpensesUS$11.29m
Earnings-US$6.25m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Sep 28, 2022

Earnings per share (EPS)-0.044
Gross Margin45.78%
Net Profit Margin-56.86%
Debt/Equity Ratio0%

How did ISR perform over the long term?

See historical performance and comparison